



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/550,299 | 05/31/2006 | Kazutoshi Watanabe | P28460 | 1935 |

| | | |
|-------------------------------|------|------------|
| 7055 | 7590 | 06/05/2007 |
| GREENBLUM & BERNSTEIN, P.L.C. | | |
| 1950 ROLAND CLARKE PLACE | | |
| RESTON, VA 20191 | | |

| EXAMINER |
|-------------------------------|
| BALASUBRAMANIAN, VENKATARAMAN |

| ART UNIT | PAPER NUMBER |
|----------|--------------|
| 1624 | |

| NOTIFICATION DATE | DELIVERY MODE |
|-------------------|---------------|
| 06/05/2007 | ELECTRONIC |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

gbpatent@gbpatent.com
pto@gbpatent.com

Office Action Summary

Application No.

10/550,299

Applicant(s)

WATANABE ET AL.

Examiner

Venkataraman Balasubramanian

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 March 2007.
2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) ☒ Claim(s) 1 and 10 is/are allowed.
6) ☒ Claim(s) 2-9 and 11-16 is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 3/14/2007.
4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

Applicants' response, which included amendment to claims 1-9 and 11-16, filed on 2/19/2007, is made of record. Claims 1-16 are pending. In view of applicants' response, the 112 first paragraph rejections, second paragraph rejections, 101 rejection and 103 rejection made in the previous office action have been obviated. However, the following rejections are applied to currently pending claims.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 12-16 are rejected under U.S.C. 112, first paragraph, because the specification while being enabling for treating, does not reasonably provide enablement for treating and preventing any or all diseases including any or neurodegenerative diseases and nay or all cancers by inhibiting tau protein kinase embraced in the claim language. The specification does not enable any physician skilled in the art of medicine, to use the invention commensurate in scope with these claims.

The instant method of use claims 12-16 are drawn to method of inhibiting and thereby treating any or all diseases including any or neurodegenerative diseases and nay or all cancers in general inhibiting tau protein kinase.

Instant claims, as recited, are reach through claims. A reach through claim is a claim drawn to a mechanistic, receptor binding or enzymatic functionality in general

Art Unit: 1624

format and thereby reach through a scope of invention for which they lack adequate written description and enabling disclosure in the specification.

In the instant case, based on the inhibition of inhibiting tau protein kinase by the instant compounds, instant claims reaches through inhibiting and treating any or all diseases in general and thereby they lack adequate written description and enabling disclosure in the specification.

More specifically, in the instant case, based on the mode of action of instant compounds as inhibitor of inhibiting tau protein kinase, based on limited assay, it is claimed that treating any or all diseases including any or all cancers in general, which there is no enabling disclosure.

The scope of the claims, any or all neurodegenerative diseases in addition to treating any or all cancer due to inhibiting tau protein kinase inhibition, which are not adequately enabled solely based on the activity of the compounds provided in the specification. Besides the generic cancer, specification also recites a list of preferred cancers for which also there is no enabling disclosure. The instant compounds are disclosed to have inhibiting tau protein kinase inhibitory activity and it is recited that the instant compounds are therefore useful in treating any or all cancer stated above for which applicants provide no competent evidence. It appears that the applicants are asserting that the embraced compounds because of their mode action as inhibiting tau protein kinase inhibitor that would be useful for all sorts of neurodegenerative diseases and cancers. However, the applicants have not provided any competent evidence that the instantly disclosed tests are highly predictive for all the uses disclosed and

Art Unit: 1624

embraced by the claim language for the intended host. Moreover many if not most of cancers, such as lung cancer, brain cancer, pancreatic cancer, colon cancer etc. and several neurodegenerative diseases are very difficult to treat and despite the fact that there are many anticancer drugs and CNS drugs..

The scope of the claims involves millions of compounds of claim 1 based on the generic definition of various variable groups as well as the thousand of diseases.

In addition, the scope of the claim includes not only treatment for any or all diseases with the huge genus of compounds but also prevention of any or all disease which is not adequately enabled solely based on the activity of the compounds as tau protein kinase inhibitors provided in the specification. "To prevent" actually means to anticipate or counter in advance, to keep from happening etc. (as per Websters II Dictionary) and there is no disclosure as to how one skilled in the art can reasonably establish the basis and the type of subject to which the instant compounds can be administered in order to have the "prevention" effect. There is no evidence of record, which would enable the skilled artisan in the identification of the people who have the potential of becoming afflicted with the disease(s) or disorder(s) claimed herein.

No compound has ever been found to treat or prevent any or all disease including any or neurodegenerative disease and cancers of all types generally. Since this assertion is contrary to what is known in medicine, proof must be provided that this revolutionary assertion has merits. The existence of such a "compound" is contrary to our present understanding of oncology. Cecil Textbook of Medicine states, "each specific type has unique biologic and clinical features that must be appreciated for

Art Unit: 1624

proper diagnosis, treatment and study" (see the enclosed article, page 1004). Different types of cancers affect different organs and have different methods of growth and harm to the body. Thus, it is beyond the skill of oncologists today to get an agent to be effective against cancers generally. Also see the PTO website

<<<http://www.uspto.gov/web/offices/pac/dapp/1pecba.htm#7>>>

ENABLEMENT DECISION TREE, Example F, situation 1) which is directed to the scope of cancers.

Note substantiation of utility and its scope is required when utility is "speculative", "sufficiently unusual" or not provided. See *Ex parte Jovanovics*, 211 USPQ 907, 909; *In re Langer* 183 USPQ 288. Also note *Hoffman v. Klaus* 9 USPQ 2d 1657 and *Ex parte Powers* 220 USPQ 925 regarding type of testing needed to support in vivo uses.

Next, applicant's attention is drawn to the Revised Utility and Written Description Guidelines, at 66 FR 1092-1099, 2001 wherein it is emphasized that 'a claimed invention must have a specific and substantial utility'. The disclosure in the instant case is not sufficient to enable the instantly claimed method treating solely based on the inhibitory activity disclosed for the compounds.

The state of the art is indicative of the requirement for undue experimentation. See *Hutton et al.*, *Trends in Molecular Medicine*, 7(10), 467-470, 2001, especially concluding paragraphs.

Also, note MPEP 2164.08(b) which states that claims that read on "... significant numbers of inoperative embodiments would render claims nonenabled when the specification does not clearly identify the operative embodiments and undue

Art Unit: 1624

experimentation is involved in determining those that are operative.". Clearly that is the case here.

In evaluating the enablement question, several factors are to be considered. Note *In re Wands*, 8 USPQ2d 1400 and *Ex parte Forman*, 230 USPQ 546. The factors include: 1) The nature of the invention, 2) the state of the prior art, 3) the predictability or lack thereof in the art, 4) the amount of direction or guidance present, 5) the presence or absence of working examples, 6) the breadth of the claims, and 7) the quantity of experimentation needed.

1) The nature of the invention: Therapeutic use of the compounds in treating various cancers that require tau protein kinase inhibitory activity.

2) The state of the prior art: Recent publication expressed that the tau kinase inhibition effects are unpredictable and are still exploratory. See *Corso et al.*, and *Kermogrant et al.*, cited above especially the concluding paragraphs.

3) The predictability or lack thereof in the art: Applicants have not provided any competent evidence or disclosed tests that are highly predictive for the pharmaceutical use for treating and preventing any or all diseases including neurodegenerative diseases and any or all cancers by the instant compounds. Pharmacological activity in general is a very unpredictable area. Note that in cases involving physiological activity such as the instant case, "the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved". See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970).

4) The amount of direction or guidance present and 5) the presence or absence of working examples: Specification has no working examples to show treating any or all cancers and the state of the art is that the effects of tau protein kinase inhibitors are unpredictable.

6) The breadth of the claims: The instant claims embrace any or all disease as noted above and scope of compound claim embrace large genus of compounds.

7) The quantity of experimentation needed would be an undue burden to one skilled in the pharmaceutical arts since there is inadequate guidance given to the skilled artisan, regarding the pharmaceutical use, for the reasons stated above.

Thus, factors such as "sufficient working examples", "the level of skill in the art" and "predictability", etc. have been demonstrated to be sufficiently lacking in the instant case for the instant method claims. In view of the breadth of the claims, the chemical nature of the invention, the unpredictability of enzyme-inhibitor interactions in general, and the lack of working examples regarding the activity of the claimed compounds towards treating the variety of cancers of the instant claims, one having ordinary skill in the art would have to undergo an undue amount of experimentation to use the instantly claimed invention commensurate in scope with the claims.

MPEP §2164.01(a) states, "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557,1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." That conclusion

Art Unit: 1624

is clearly justified here and undue experimentation will be required to practice Applicants' invention.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 2-9 and 11 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 of U.S. Patent No. 6,844,335. Although the conflicting claims are not identical, they are not patentably distinct from each other because the compound and composition embraced in the instant claims overlaps with the method of use embraced in claims 1-50 of US 6,844,335. Note claim 1 of the US patent relates to compounds wherein R¹ and R² form a ring. Thus, it would have been obvious to one having ordinary skill in the art at the time of the invention was made to make compounds wherein R¹ and R² form a ring using the teachings of US

Art Unit: 1624

6,844,335 and expect resulting compounds to possess the uses taught by the art in view of the equivalency teaching outline above.

This rejection is same as made in the previous office action. Applicants' traversal to overcome this rejection is not persuasive. The said US patent permits substitutions in piperazine ring and claims 2-9 and 11 include compounds with no substitution as well. Hence one trained in the art would be motivated to make the compounds wherein R^1 and R^2 form a ring with or without any substituents in the ring. Hence, this rejection is proper and is maintained.

Claims 2-9 and 11 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-25 of copending Application No. 11/035,264. Although the conflicting claims are not identical, they are not patentably distinct from each other because the subject matter embraced in the instant claims is also embraced in the copending application. Note when R^3 is pyridyl and X is N, compounds, composition and method of use embraced in the copending application overlap with the those of instant claims.

Thus, it would have been obvious to one having ordinary skill in the art at the time of the invention was made to make compounds wherein R^1 and R^2 form a ring using the teachings of 11/035,264 and expect resulting compounds to possess the uses taught by the art in view of the equivalency teaching outline above.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

This rejection is same as made in the previous office action. Applicants' traversal to overcome this rejection is not persuasive. The said US patent permits substitutions in piperazine ring and claims 2-9 and 11 include compounds with no substitution as well. Hence one trained in the art would be motivated to make the compounds wherein R¹ and R² form a ring with or without any substituents in the ring. Hence, this rejection is proper and is maintained.

Applicants should note that claims 2-11 are improper dependent claims as they permit m=0 choice not recited in claim 1.

Allowable Subject Matter

Claims 1 and 10 , barring find of any prior art in a subsequent search, are allowed.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1624

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication from the examiner should be addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (571) 272-0662. The examiner can normally be reached on Monday through Thursday from 8.00 AM to 6.00 PM. The Acting Supervisory Patent Examiner (SPE) of the art unit 1624 is James O. Wilson, whose telephone number is 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned (703) 872-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAG. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-2 17-9197 (toll-free).


Venkataraman Balasubramanian

5/28/2007